JASPER THERAPEUTICS, INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 45
- Market Cap
- $305.8M
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06736262
- Locations
- 🇺🇸
Investigative Site 116, Tampa, Florida, United States
🇺🇸Investigative Site 109, Boise, Idaho, United States
🇺🇸Investigative Site 124, Normal, Illinois, United States
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06592768
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06353971
- Locations
- 🇩🇪
Charité - University Clinic Berlin, Berlin, Germany
🇩🇪University Hospital Dresden, Dresden, Germany
🇩🇪Medical University Hannover, Hannover, Germany
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Other: Placebo
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06162728
- Locations
- 🇩🇪
Site 202, Marburg, Germany
🇩🇪Site 210, München, Germany
🇩🇪Site 204, Münster, Germany
JSP191 (briquilimab) in Subjects with LR-MDS
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05903274
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
- Conditions
- MYELODYSPLASTIC SYNDROME; MDSACUTE MYELOID LEUKEMIA; AML
- Interventions
- Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04429191
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
JSP191 Antibody Targeting Conditioning in SCID Patients
- Conditions
- SCID
- Interventions
- Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02963064
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸UCLA Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States